DATE: THURSDAY, FEBRUARY 6TH
TIME: 1:30 - 5:00 PM
TODAY & TOMORROW
BRINGING GENE EDITING TECHNOLOGY FROM LABORATORY TO BEDSIDE
This program will provide an overview of the opportunities and challenges expected in bringing genome editing from the laboratory to the beside. Hear from leading experts on the science behind genome editing; challenges in the IP landscape; learn about what is happening at NIST to set industry standards; hear about anticipated challenges from a public policy perspective, and gain a high-level overview on product development strategies to ensure plans are scientifically sound and meet regulatory expectations and clinical objectives.
MAIKEN SCOTT BIO
WHYY is Greater Philadelphia’s leading public media provider and PBS/NPR member station, serving southeastern Pennsylvania, southern New Jersey and all of Delaware.
ERIC KMIEC, PH.D. BIO
Under Dr. Kmiec’s leadership, the Gene Editing Institute has become a leader in gene editing and biomedical research in cancer and other inherited disease. It is the only institute of its kind embedded in a community cancer center where interactions among oncologists, genetic counselors and patients take place. This unique collaboration brings translational cancer research – from innovative basic science directly to patient treatment – to an entirely new level.
In April 2018, the team announced a major new development in the CRISPR Journal of the first CRISPR gene-editing tool to allow DNA repairs outside the human cell. The new “cell free” technology uses a protein called Cpf1 or Cas12a, that allows researchers to make multiple edits to DNA samples quickly and more precisely in vitro, that is, in a test tube or petri dish. This capability has generated unprecedented excitement about developing different CRISPR tools that could produce breakthrough treatments for a wide range of diseases by repairing a damaged gene, modifying it or deleting it entirely.
Thanks to a $1 million grant from the National Science Foundation in 2017, the Gene Editing Institute is collaborating with Delaware Technical Community College to develop the first-ever gene editing curriculum for community college students in Delaware and across the nation.
Dr. Kmiec is the recipient of multiple research awards from the National Institutes of Health (RO1s, R21s), the American Cancer Society, the Binational Industrial Research and Development (BIRD) Foundation and other private foundations including the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease. He has been a member of numerous editorial boards, NIH study sections and review boards and is the (primary or corresponding) author of more than 155 scientific publications (mostly in genetic recombination and gene editing).
Dr. Kmiec has been the primary mentor for 18 Ph.D. students and 4 MS students, all of whom have attained scientific positions. He has held or holds major administrative posts on various NIH regional and state biomedical research grants, including IDeA Network of Biomedical Research (INBRE) and Centers of Biomedical Research Excellence (COBRE). Dr. Kmiec was also honored as the Eminent Scholar in residence at Marshall University (Huntington, West Virginia) in 2009-2011 and was elected as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in Dover, Delaware for in 2013 and again in 2014.
SAMANTHA MARAGH, PH.D. BIO
Samantha also represents the U.S. as a technical expert to the International Standards Organizations Technical Committee on Biotechnology (ISO TC 276). She is currently the U.S. liaison representing the interests and expertise of the U.S. on standards relating to nucleic acids measurements.
MARITZA MCINTYRE, PH.D. BIO
ROBERT OAKES BIO
Prior to joining the firm, Mr. Oakes worked in the legal department of Johnson & Johnson (2006), and obtained technical experience at the Louis Berger Group (2004-2005) and Kansas State University (2002-2003).
PATRICK PLUES BIO
Most recently, Patrick was Vice President for Government Affairs at The Conafay Group, a government and public affairs consulting firm specializing in the biopharmaceutical industry. Prior to The Conafay Group, he was Director of Federal Government Affairs at Cephalon, a global biopharmaceutical company where he was responsible for executing federal legislative/ policy strategies and representing company interests before the U.S. Congress and the Administration. He also led a team of alliance development and health policy and reimbursement professionals.
Before Cephalon, Patrick worked in the public affairs department of Wyeth Pharmaceuticals, one of the largest research-based biopharmaceuticals companies in world. His responsibilities included third-party alliance development, PAC administration, and grassroots management.
Patrick began his career on Capitol Hill working in the U.S. House of Representatives. He holds a BS in Political Science from West Virginia University and currently resides in New Hope, Pennsylvania.
WHO SHOULD ATTEND
WHY YOU SHOULD ATTEND
SCHEDULE OF EVENTS
1:45 – 2:15 PM | Intro to Genome Editing and CRISPR
2:15 – 2:30 PM | Standard Setting for Genome Editing and CRISPR
2:30 – 2:45 PM | The Legal Challenges and Breakthroughs for Genome Editing and CRISPR
2:45 – 3:00 PM | Preparing for Commercialization
3:00 – 3:15 PM | Break
3:15 – 3:30 PM | Public Policy Perspective for Genome Editing and CRISPR
3:30 – 5:00 | Moderated Panel and Audience Questions
You must register in advance in order to attend this event. Walk-ins will not be accepted. Thank you!
Cancellations must be made in writing, via email to Yvette Murray at [email protected], more than one (1) week prior to the event to receive a refund minus 25% for registration/administrative costs. If the cancellation is made within one week of the event or the attendee is a no-show, Delaware Bio will not issue a refund. If you have any questions or concerns, please contact Yvette Murray at [email protected].